Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
11466 studies found for:    NCI
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Not yet recruiting Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Lymphoma;   Recurrent Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm
Interventions: Drug: ALK Inhibitor X-396;   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Trk Inhibitor LOXO-101;   Drug: Vemurafenib
2 Recruiting Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Condition: Epithelioid Hemangioendothelioma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Drug: Trametinib
3 Not yet recruiting Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelin Positive;   Pleural Malignant Mesothelioma
Interventions: Biological: Anetumab Ravtansine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study
4 Not yet recruiting MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Gliosarcoma;   Recurrent Glioblastoma;   TP53 wt Allele;   Unmethylated MGMT Promoter
Interventions: Other: Laboratory Biomarker Analysis;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study;   Radiation: Radiation Therapy
5 Not yet recruiting Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Adult Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
6 Not yet recruiting Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Refractory Mycosis Fungoides;   Stage IB Mycosis Fungoides and Sezary Syndrome;   Stage II Mycosis Fungoides and Sezary Syndrome;   Stage IIA Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage III Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IV Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Biological: Interferon Gamma-1b;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
7 Recruiting Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Conditions: Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Patient Observation;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
8 Recruiting Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
Conditions: Metastatic Transitional Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   TSC1 Gene Mutation;   TSC2 Gene Mutation
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Sapanisertib
9 Not yet recruiting MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   TP53 wt Allele;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study
10 Not yet recruiting Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
Conditions: KRAS NP_004976.2:p.G12R;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib Sulfate
11 Not yet recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Epstein-Barr Virus-Positive Mucocutaneous Ulcer;   Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma;   High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   Human Herpesvirus-8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   MYC-Negative B-Cell Lymphoma With 11q Aberration Resembling Burkitt Lymphoma;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Skin Ulcer;   Small Intestinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Varlilumab
12 Not yet recruiting Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant
Condition: Solid Organ Transplantation Recipient
Interventions: Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
13 Not yet recruiting Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery
Conditions: Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
14 Not yet recruiting MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Hypercalcemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study
15 Not yet recruiting Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Conditions: Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Recombinant Interleukin-12
16 Not yet recruiting Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma;   Grade 2 Endometrial Endometrioid Adenocarcinoma;   Grade 3 Endometrial Endometrioid Adenocarcinoma;   Uterine Corpus Adenosarcoma
Interventions: Drug: Entinostat;   Procedure: Hysterectomy;   Other: Laboratory Biomarker Analysis;   Drug: Medroxyprogesterone Acetate
17 Not yet recruiting Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Metastatic Malignant Neoplasm in the Lymph Nodes;   Recurrent Gastric Carcinoma;   Stage IV Gastric Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Biological: Ramucirumab
18 Not yet recruiting Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer
Conditions: Colorectal Adenocarcinoma;   High-Frequency Microsatellite Instability;   Stage IV Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
19 Recruiting Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Conditions: Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Ropidoxuridine;   Radiation: Whole-Brain Radiotherapy
20 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.